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Inflammation is the most common cause of death worldwide. Mediated by the 
innate immune system, inflammation serves as one of the first lines of defense against 
infection and injury. However, when this natural and healthy response runs amok, it can 
cause and exacerbate many diseases. The innate immune receptor Toll-like Receptor 4 
(TLR4), along with its cofactors, MD-2 and CD14, activates inflammation in response 
to external and internal danger signals. TLR4 induced inflammation is implicated in 
sepsis and many other inflammatory disease states. Despite the significance of this 
receptor complex for human health, much is yet to be understood regarding the 
biochemical mechanism by which it recognizes danger signals. In particular, the role of 
the cofactor CD14 is well understood for external danger signals, but its role in internal 
danger signal recognition is poorly understood. By introducing mutations to CD14 and 
measuring their effect on TLR4 induced inflammation, I have determined the 
importance of specific amino acids and regions of CD14 involved in activation by 
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Inflammation is a double-edged sword. When faced with injury or infection, 
inflammation serves to protect us. When we get sick with a flu or cold, common 
symptoms such as fever and chills are not due to the infection itself. Instead, this 
response is our body activating inflammation, which helps clear the virus from our 
bodies. When a tissue is inflamed, it recruits white blood cells. These white blood cells 
secrete highly reactive molecules that non-specifically damage both germs and our own 
cells. Our bodies sacrifice a few replaceable cells in an effort to kill the invading 
viruses. This healthy and natural response produced by our immune system allows us to 
handle various challenges. Without inflammation as an initial response, our bodies 
would have a difficult time staving off even the smallest of infections. However, 
inflammation becomes less beneficial the longer it occurs—while acute inflammation 
can prevent serious infection, chronic inflammation can have grave consequences for 
human health. Many diseases either cause or are marked by chronic inflammation 
(Pahwa et. al, 2020). Diabetes, cardiovascular disease, autoimmune diseases, 
Alzheimer’s, and cancer are all chronic inflammatory diseases, and contribute to 3 in 5 
deaths worldwide (Pahwa et. al, 2020). In each of these disease states, chronic 
inflammation leads to chronic tissue damage and thus, poor health outcomes. How our 
bodies maintain this delicate balance of clearing infections without inducing chronic 
inflammation has been a topic of intensive study for many years.  
Inflammation is controlled by the innate immune system. The innate immune 
system is thought to have evolved as early as 500-600 million years ago (Buchmann, 




pathogens are present (Buchmann, 2014). Composed of a variety of different Pattern 
Recognition Receptors (PRRs), the innate immune system can recognize and respond to 
molecules that are unique to microbes (Buchmann, 2014).  These Microbe-Associated 
Molecular Patterns (MAMPs) are thus chemical hallmarks of pathogens. Upon 
recognition, innate immune receptors trigger a non-specific immune response to create 
an inhospitable environment for the pathogen, such as inflammation and fever 
(Buchmann, 2014). It is also sometimes advantageous for human cells to activate a local 
inflammatory response in the absence of pathogens. For example, in wound healing 
inflammation occurs even in a sterile environment. To activate inflammation, immune 
cells produce molecules known as Damage Associated Molecular Patterns (DAMPs) 
that activate PRRs in a fashion analogous to MAMPs (Alberts, 2008).  
Toll-like receptors 
While there are many different classes of innate immune receptors, one group 
that is heavily studied and can recognize a wide variety of MAMPs is known as the 
Toll-like receptors (TLRs). TLRs first arose in multicellular invertebrates, such as 
cnidarians and sponges, but have expanded in number and specificity throughout 
evolutionary time (Buchmann, 2014). Humans have 10 TLR receptors, each specialized 
to recognize a specific MAMP (Christmas, 2010). For example, the heterodimer of 
TLR2 and TLR1 recognizes triacylated lipopeptides (found in bacteria), whereas the 
heterodimer of TLR7 and TLR8 recognizes ssRNA (found in viruses) (Uematsu & 
Akira, 2008).  The homodimer of TLR4, the receptor complex which I am studying, is 
the canonical receptor for lipopolysaccharide (LPS), which is a cell-wall component of 




TLR4 has important implications for human health—its response to LPS 
contributes to sepsis, which caused 1 in 5 deaths worldwide from 1990 – 2017. TLR4 
induced inflammation can also be hijacked by cancerous cells, which produce DAMPs 
that activate TLR4 to promote blood vessel growth in growing tumors. The discovery of 
TLR4 in 1998 by the Beutler lab earned the Nobel Prize in Physiology or Medicine in 
2011 (Rudd et. al, 2020). TLR4 is present on the cell membranes of a variety of cell 
types, including blood-cell progenitors and immune cells (Molteni. et. al, 2016). TLR4 
acts as a complex with two accessory proteins, MD-2 and CD14; together, they 
recognize and respond to both MAMPs and DAMPs.  
LPS is a molecule made exclusively by gram-negative bacteria. It contains three 
main parts: the O antigen, core oligosaccharides, and Lipid A tails (Figure 1), with the 
lipid A portion being primarily responsible for pathogenicity. The size and structure of 
LPS varies greatly between bacterial species, with modifications occurring to the O 
antigen, core oligosaccharides, and lipid A tails. While various forms of LPS exist, the 
two main forms used to test activation of TLR4 are LPS-S and LPS-R derived from S. 
enterica and E. coli bacteria, respectively. LPS-R lacks the O antigen, whereas LPS-S 







Figure 1: Subsections of LPS, labeled. Obtained from Sigma Aldrich 
TLR4 is also activated by a variety of DAMPs.  One important TLR4 DAMP is 
S100A9. This protein is 14 kDa in size, acts as a calcium binding protein, and 
frequently occurs as a homodimer (Markowitz & Carson, 2013). It is much larger than 
LPS and does not contain any analogous structure to the long hydrophobic tails of the 
lipid-A portion of LPS. Very little is understood regarding how S100A9 activates 




can gain insight into not just how this specific system works, but also learn more about 
how DAMPs and TLRs may interact.  
 
Figure 2: Two views of the crystal structure of human S100A9 Homodimer. 
Each individual S100A9 molecule labeled in green or orange. Obtained from RSCB 
PDB. PDB ID: 1IRJ 
Mechanism of TLR4 activation 
TLR4 is composed of an intra- and extracellular domain, connected by a 
transmembrane helix (Molteni et. al, 2016). The extracellular domain of TLR4, along 
with MD-2, recognizes both DAMPs and MAMPs (Molteni et. al, 2016). In the case of 
LPS, the hydrophobic lipid tails of LPS bind inside a pocket of MD-2, while its polar 
charged head and O antigen interact with the outside of MD-2 and parts of TLR4 (Park 
et. al, 2009). A crystal structure of LPS bound to the TLR4/MD-2 complex has been 
solved, which shows the direct interaction of TLR4/MD-2 with LPS in detail (Park et. 
al, 2009). This binding event promotes dimerization with a second molecule of 
TLR4/MD-2 bound to LPS (Molteni et. al, 2016). Dimerization induces a 
conformational change in the intracellular domains of TLR4 and facilitates the 




inflammation through the production of NF-kB, a promoter of many genes involved in 
inflammation, and various pro-inflammatory cytokines (Molteni et. al, 2016).  
The cofactor CD14 is also essential for TLR4’s ability to recognize and respond 
to LPS. CD14 is anchored to the cell membrane on one side and has an LPS binding 
pocket on the other side. CD14 shuttles LPS to the TLR4/MD-2 complex, where it is 
passes from CD14 to its binding location on the TLR4/MD-2 complex. CD14 is 
necessary for the recognition of LPS by the TLR4 complex for two main reasons—it 
allows TLR4 to recognize LPS at lower concentrations promoting a swift immune 
response to microbes and protects the hydrophobic tails of LPS from interacting with 
other hydrophobic molecules in the cell (Granucci & Zanoni, 2013). Previous research 
has shown that LPS binds to CD14 in the N-terminal pocket (Juan et. al, 1995, He et. al, 
2016). While both binding and activation assays have shown this portion of CD14 to 
contain the LPS binding site, and specific residues have been found to play important 
roles, there is no crystal structure of LPS bound to CD14.  
While a great deal of research has been conducted regarding the interaction of 
LPS with the TLR4 complex, the exact mechanism of activation of TLR4 via S100A9 is 
largely unknown. In vitro activity studies have shown that both CD14 and MD-2 are 
necessary for activation via S100A9. Intriguingly S100A9 and CD14 co-localize on cell 
membranes in vivo and have even been shown to directly bind in vitro (He et. al, 2009). 
Despite this clear evidence for the existence of an interaction between S100A9 and 
CD14, little is known about the nature of the interaction. Thus, the main questions 




specific sites and regions involved; and, is this interaction different than the LPS/CD14 
interaction (Figure 3)?  
 
Figure 3: Illustration of research question and system.  
Figure created using BioRender. 
 
Investigating this question will provide valuable insight into exactly how 
S100A9 interacts with the TLR4 complex. Since elevated levels of S100A9 are 
associated with a variety of conditions, including but not limited to arthritis, diabetes, 
septic shock, Alzheimer’s, cancer, and even serious COVID-19 infection outcomes, 
learning more about where S100A9 interacts with CD14 can help inform the creation of 
possible drug targets (Pahwa et. al, 2020; Wang et. al, 2013; Källberg et. al, 2012; Gong 
et. al, 2019; Averill et. al, 2012, Barnes & Karin, 1997). Previous research has 
attempted to make anti-S100 family drugs, but such drugs failed during clinical trials 




Understanding how S100A9 directly interacts with CD14, could provide insights 
to a possible drug target—one that allows for activation of TLR4 via LPS to maintain 






To attempt to answer my research question, a truncation mutant of CD14 
informed by existing literature was generated to determine the overall region required 
for CD14 function. I then used site-directed mutagenesis to introduce single amino acid 
substitutions within that region (Table 1). Like all proteins, CD14 is a long chain of 
specific amino acids connected end-to-end. Different amino acids have different 
physiochemical properties, thus allowing proteins to interact specifically with other 
molecules that have matched physiochemical properties. In site-directed mutagenesis, I 
swapped out one amino acid at a specific point in the chain with another amino acid 
with different properties. This allowed me to test whether the amino acid in the protein 
is important for a given function.  The creation of these mutants was informed by three 
main strategies: previous literature, conservation analysis, and structural analysis.  
Mutation1 Cofactor Reasoning Literature 
D29K CD14 Mutation found to reduce LPS 
binding by >50%. 
Cunningham et al, 
2000 
R33E CD14 Mutation found to reduce LPS 
binding by >50%. 
Cunningham et al, 
2000 
E56K CD14 Mutation found to reduce LPS 
binding by >50%. 
Cunningham et al, 
2000 
W45A CD14 Encircles the rim with its side chain 
overlaying the entrance to the LPS 
binding pocket. 
Kelly et al., 2013 
F49A CD14 Encircles the rim with its side chain 
overlaying the entrance to the LPS 
binding pocket. 
Kelly et al., 2013 
V52A CD14 Encircles the rim with its side chain 
overlaying the entrance to the LPS 
binding pocket. 
Kelly et al., 2013 
F69A CD14 Encircles the rim with its side chain 
overlaying the entrance to the LPS 
binding pocket. 
Kelly et al., 2013 
                                                        
1 A list of the twenty amino acids, along with their abbreviated names and chemical properties can be 




Y82A CD14 Encircles the rim with its side chain 
overlaying the entrance to the LPS 
binding pocket. 
Kelly et al., 2013 
L89A CD14 Encircles the rim with its side chain 
overlaying the entrance to the LPS 
binding pocket. 




CD14 Truncation of CD14 only containing 
N-terminal 152 amino acids has 
been shown to retain activation 
ability 
Juan et. al, 1995 
Table 1: List of mutations with reasoning and referenced literature. 
Previous Literature 
Previous research has tested the interaction of CD14 with LPS; some of these 
studies include direct binding assays or activation assays and utilize the introduction of 
mutations or blocking antibodies with known binding sites. After looking at previous 
literature that introduced mutations to CD14, I chose to select a few mutants from these 
studies. Research conducted by Juan et. al in 1995 indicated that a truncation of CD14 
than only contained the N-terminal 152 amino acids was still able to activate TLR4 via 
LPS, however, this mutant has not been tested with S100A9. Additionally, research 
conducted by Cunningham et. al in 2000 demonstrated that three mutants, D29K, R33E, 
and E56K all decreased binding of LPS with CD14 by greater than 50%. Like the 
truncation of CD14, these mutants were also not tested with S100A9. By treating these 
mutants with both S100A9 and LPS, I hoped to gain some insight into whether the two 
ligands may bind CD14 in a similar location.  
Structural Analysis 
Some of the mutants were created based on the known crystal structure of 
CD14. It is known that LPS binds to CD14 in the N-terminal hydrophobic pocket. By 




in the pocket, I chose to mutate residues in the rim of the pocket whose side chains 
stuck into the entrance (Figure 4).  
 
Figure 4: Crystal Structure of human and mouse CD14 with mutations labeled.  
Human rim residues are colored in red, and mouse rim residues are colored in blue. 
Mutations are circled in green and are occurring on human CD14. Original image 
obtained from Kelly et. al, 2003, with annotations of selected residues added by author. 
 These mutations were: W45A, F49A, V52A, F69A, Y82A, and L89A. By 
seeing how these mutants affected the activation of TLR4 via S100A9, I hoped to gain 
additional insight into whether S100A9 and LPS may share the N-terminal binding 
pocket.  
Conservation Analysis 
To further inform mutant generation, I also performed a conservation analysis 
on the residues of CD14 (Figure 5). Residues that stayed as the same amino acid across 
evolutionary time were considered highly conserved, whereas residues that did not stay 




looked at those results to see if any of the residues I chose to mutate on CD14 were 
highly conserved.  
 
Figure 5: Crystal structure of human CD14 as surface representation. 
Conserved residues labeled in red. The left side of the molecule in the above image is 
the N-terminus. Image generated with PyMol.  
Individual amino acids that are more highly conserved across evolutionary time 
are likely facing selective pressure; the amino acid that is highly conserved may 
participate in an important interaction (such as binding with a ligand) or have an 
important structural role. If the mutants I chose were important for binding with either 
LPS or S100A9, they also may be highly conserved. Ultimately, I found that of the 
residues I had chosen to mutate, only residues D29 and L89 were highly conserved. 
However, the conservation analysis I performed only indicated that the specific amino 
acid was conserved, not whether the chemical properties of the amino acid (which can 





To test TLR4 activation I performed a widely used transfection-based activity 
assay. The mutants of CD14 I created were transfected into Human Embryonic Kidney 
(HEK) 293T cells, along with the wild-type TLR4 and MD-2, pcDNA, renilla, and 
ELAM-luciferase.  The pcDNA plasmid acted as “junk” DNA to improve transfection 
efficiency, whereas the renilla and ELAM-luciferase plasmid acted as luminescent 
reporters. These reporters were used to measure transfection efficiency and TLR4 
activation, respectively.  
 
Figure 6: Illustration of transfection, treatment, and activation assay.  
Image created with BioRender. 
The ELAM-luciferase plasmid contained an NF-kB promoter for the firefly 
luciferase enzyme gene. When NF-kB was not present, the firefly luciferase gene was 
not transcribed, and firefly luciferase was not created. However, when TLR4 was 
activated, NF-kB was generated, which promoted expression of the luciferase firefly 




luciferase enzyme cleaved this protein, causing it to luminesce (Figure 7). I then 
measured the intensity of this emitted light to determine the degree of activation; cells 
that had higher levels of activation created more NF-kB, resulting in the production of 
more firefly luciferase enzyme and a greater luminescence intensity.  
Unlike the firefly luciferase, all cells that were successfully transfected 
expressed renilla luciferase from the renilla plasmid. Then, when I analyzed the cells, I 
also added the renilla substrate. This substrate was cleaved by the renilla luciferase 
enzyme and luminesced (Figure 7). I was then able to measure the intensity of the 
emitted light to determine how many cells were present in the assay. This allowed me to 
normalize the output of my firefly luciferase reporter.  
 
Figure 7: Firefly luciferase and Renilla luciferase reporter assay 
Illustration of Firefly luciferase and Renilla luciferase reporter assay. Image created 
with BioRender. 
To determine how each mutation to CD14 affects the ability of LPS and S100A9 




ng/mL LPS and 2uM S100A9 treatments were used to measure how the mutants affect 
activation of TLR4 at saturating concentrations of either ligand. Treatment of 200 
ng/mL LPS and Polymyxin B (PB) acted as a negative control; PB binds to and 
sequesters LPS, preventing activation of TLR4. The treatment of 2uM S100A9 and PB 
acted as a more accurate measure of how the mutants affect the activation of TLR4 via 
S100A9. Because S100A9 is expressed and purified from E. coli, which contains LPS, 
contaminating LPS is likely present. The addition of PB to the S100A9 treatment 
removes any LPS that may be present in the sample. This allowed me to see the effect 
of the mutant on the activation of TLR4 via S100A9 only. The last treatment type, PBS 
(phosphate buffered saline) Buffer, acted as a negative control. (Table 2).  
Treatment Description and Reasoning 
200 ng/mL LPS Saturating concentration of LPS; test effect of CD14 
mutants on TLR4 activation via LPS.  
2 uM S100A9 Saturating concentration of S100A9; test effect of 
CD14 mutants on TLR4 activation via S100A9.  
200 ng/mL LPS + PB Negative control; PB sequesters LPS, preventing 
TLR4 activation. 
2 uM hS100A9 + PB Purification of S100A9 sample; removes any LPS 
contaminant reducing background noise generated by 
possible activation of TLR4 via LPS.  
PBS Negative control; buffer.  
 
Table 2: Description and reasoning of various treatments. 
 
Transfection of cells with no CD14 also acted as an additional negative control, 




Following 3-4 hours of treatment, I removed the treatment mix, and analyzed the cells 
for activity using the renilla luciferase and firefly luciferase reporters as previously 
described.  
Data Analysis 
I measured the normalized activation intensity by using the equations presented 
in Equations 1. I calculated the normalized luminescence by dividing the raw firefly 
luminescence intensity by the raw renilla luminescence intensity. I then subtracted a 
blank (the data for No CD14 + LPS, which was a negative control) from the normalized 
luminescence to get the corrected luminescence value for each well. Next, I normalized 
this value by dividing it by the average corrected luminescence of the WT + LPS or WT 
+ A9 + PB treatment. Finally, to get the normalized activity for each mutant and 
treatment, I averaged three technical replicates for each mutant and treatment 





𝑏𝑏𝑛𝑛𝑛𝑛𝑛𝑛𝑏𝑏 𝑛𝑛𝑙𝑙𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑙𝑙𝑙𝑙𝑛𝑛𝑛𝑛𝑙𝑙𝑛𝑛 = 𝑛𝑛𝑎𝑎𝑎𝑎. (𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑛𝑛𝑙𝑙𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑙𝑙𝑙𝑙𝑛𝑛𝑛𝑛𝑙𝑙𝑛𝑛𝑁𝑁𝑁𝑁 𝐶𝐶𝐶𝐶14+𝐿𝐿𝐿𝐿𝐿𝐿) 
𝑛𝑛𝑙𝑙𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑙𝑙𝑙𝑙𝑛𝑛𝑛𝑛𝑙𝑙𝑛𝑛 = 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑛𝑛𝑙𝑙𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑙𝑙𝑙𝑙𝑛𝑛𝑛𝑛𝑙𝑙𝑛𝑛 − 𝑏𝑏𝑛𝑛𝑛𝑛𝑛𝑛𝑏𝑏 𝑛𝑛𝑙𝑙𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑙𝑙𝑙𝑙𝑛𝑛𝑛𝑛𝑙𝑙𝑛𝑛 














I also averaged three biological replicates of each mutant with each treatment 
and calculated the standard error across biological replicates.  I calculated the P-values 
using a one sample, two-tailed t-test comparing each value to wild-type, which was 





Amino acids 1-152 of CD14 are sufficient for activation of TLR4 via LPS and 
S100A9 
Previous research has shown that only the N-terminal 152 amino acids of CD14 
are sufficient for activation of TLR4 via LPS, but this truncation mutation has not been 
tested with S100A9 (Juan et. al, 1995). To test whether S100A9 binding with CD14 
also occurs in the N-terminal 152 amino acids, HEK293T cells were transfected with 
the N-terminal 152 amino acid truncation of CD14 along with WT TLR4 and MD, and 
luminescent reporter plasmids. The transfected cells were treated with various 
treatments including S100A9 (Table 2). As expected, we observed that both LPS and 
S100A9 were able to activate TLR4 with CD14, but not without (Figure 8, dark grey 
and light grey bars). Addition of truncated protein was able to restore activity for both 
LPS and S100A9 (Figure 8, medium grey bars). These preliminary results indicate that 
S100A9 requires only the N-terminal 152 amino acids of CD14 to activate TLR4 





Figure 8: Relative Activity of TLR4 with truncated CD14 when treated with S100A9 
or LPS.  
Observed relative activity of TLRR4 with N-terminal 152 amino acid truncation of 
CD14 when treated with 2uM S100A9 + PB and 200ng/mL LPS-R. Bars show mean 
fold activation in the assay relative to the 200 ng/mL LPS control. Error bars are the 
standard error of three technical replicates. Treatments are shown below each set of 
bars. Dark, medium, and light grey bars indicate the WT, truncated, and no CD14, 
respectively. Data collected and figured created by Lauren Lehmann. 
Mutations D29K and W45A to CD14 decrease activation ability of LPS and 
S100A9 
HEK293T cells were also transfected with a series of single amino acid 
substitution CD14 mutants, and measured for activity following treatment (Table 1, 
Table 2). The two mutants with the most striking changes to activation were D29K and 
W45A. Cells transfected with these CD14 mutations showed a statistically significant 
decrease in TLR4 activity upon treatment with either S100A9 or LPS (Figures 9, 10). 




activate TLR4 and suggest that S100A9 and LPS may share these amino acids for 
binding.  
Mutation F49A to CD14 decreases activation of TLR4 via S100A9 by 50% but has 
no effect on LPS activation ability 
Unlike mutations D29K and W45A, we observed one mutation that showed 
varying effects of TLR4 activation dependent on treatment. Cells transfected with the 
F49A mutation to CD14 showed a statistically significant decrease of around 50% in 
TLR4 activation when treated with S100A9 and PB, but no effect when treated with 
LPS (Figures 9, 10). These results suggest that while LPS and S100A9 may share some 
residues for binding, there still may be some slight variations in all the residues 
important for binding each ligand.  
Select mutations to CD14 do not affect the ability of LPS or S100A9 to activate 
TLR4 
HEK293T cells were also transfected with the following mutations: R33E, 
E56K, V52A, F69A, Y82A, and L89A. These mutations resulted in no significant 
change in activation when treated with either ligand when compared to WT (Figures 9, 
10). Notably, mutations R33E and E56K, which were shown in previous research to 
decrease LPS binding by 50%, showed no effect on activation of TLR4 via either ligand 
(Figure 9). These results further suggest that LPS and S100A9 may share a similar 
binding location, or that while these residues may participate in binding both ligands, 






Figure 9: Relative activity of TLR4 with various CD14 mutants when treated with 200 
ng/mL LPS-R  
Observed relative activity of TLR4 with CD14 mutants D29K, R33E, W45A, F49A, 
V52A, E56K, F69A, Y82A, and L89A when treated with 200 ng/mL LPS-R. *** 
indicates a p value < 0.001. Bars show mean fold activation in the assay relative to the 
200 ng/mL LPS control. Error bars are the standard error of three biological replicates.  
 
Figure 10: Relative activity of TLR4 with various CD14 mutants when treated with 




Observed relative activity of TLR4 with CD14 mutants D29K, R33E, W45A, F49A, 
V52A, E56K, F69A, Y82A, and L89A when treated with 2 uM S100A9 + PB. *** 
indicates a p value < 0.001, * indicates a p value < 0.05. Bars show mean fold 
activation in the assay relative to the 2uM S100A9 + PB control. Error bars are the 






Treatment of HEK293T cells containing the CD14 truncation with S100A9 or 
LPS showed that activity of TLR4 via both ligands was retained. This data suggests that 
both ligands only require the N-terminal 152 amino acids for activation, and that within 
this region lies their binding site(s). These results are consistent with previous data 
regarding the truncation with LPS treatment and align with our understanding of the 
role of the C-terminus. In full-length versions of CD14, the C-terminus acts as an 
anchoring point between CD14 and the cell membrane; due to this, only the N-terminal 
amino acids would be available for ligand binding and transfer to TLR4/MD-2.   
 Of the nine CD14 point mutants tested, two mutants had striking effects on 
activation. Both D29K and W45A showed a significant decrease in activation in the 
presence of both mutants. Based on the crystal structure of CD14, blocking antibody 
tests, and MD (molecular dynamics) simulations regarding its interaction with LPS and 
the TLR4 complex, it is likely that the residue D29 is involved in the interaction 
between CD14 and MD-2, rather than as a binding partner for S100A9 or LPS (Juan et. 
Al, 1995, Kim et. Al, 2005). Because this assay measures activation and not direct 
ligand binding, the results collected do not inform us of whether the mutation affected 
binding directly or affected activation through some other means. Due to this, the 
results collected for the D29K mutation could indicate that it interfered with the ability 
of CD14 to bind with TLR4/MD-2, rather than disrupting binding with both ligands.  
The mutation W45A also seemed to affect the activation of TLR4/MD-2 via 
LPS and S100A9. Based on our understanding of the interaction between CD14 and the 




are other possible explanations that could account for these results. W45A could disrupt 
the binding of S100A9 and LPS to CD14; this would mean that W45 was a residue 
necessary for both interactions. Another possible explanation is that the mutation could 
have affected expression of CD14. When genes are transcribed from DNA to RNA and 
then translated from RNA to proteins, the process can occasionally fail. Certain 
sequences and chemical properties can alter this efficiency, resulting in very little 
protein production, despite ample gene expression. It is possible that the mutation 
W45A may have altered the chemical properties of the protein that makes it more 
difficult to translate. This would cause lower levels of CD14 expression, and therefore 
lower levels of activation in the presence of either ligand.  
Unlike D29K and W45A, F49A seemed to affect LPS and A9 differently. This 
could indicate a few possibilities. If D29K and W45A are not within the binding site of 
both S100A9 and LPS, it is possible that F49A only lies within the binding site of LPS, 
and that S100A9 occupies a different binding site. If D29K and/or W45A are found to 
be within the binding sites of both molecules, it could instead indicate that while 
S100A9 and LPS may share the same overall binding site, there may be differences 
between specific residues involved in the interaction between the two ligands.  
Future Directions 
One main limitation of this experiment is that it only utilizes a TLR4 activity 
assay. Because it does not directly test binding between CD14 and ligand, interpreting 
the results to inform binding interactions can be somewhat limited. As seen with D29K, 
it is possible that some mutations may affect the ability of CD14 to interact with MD-




how these mutants affect binding, a coimmunoprecipitation experiment could be 
performed. By conducting a pull-down assay with various CD14 mutants and S100A9 
or LPS, we could gain some insight into whether these mutations directly disrupt 
binding. Furthermore, we could also perform the experiment with wild type CD14 in 
the presence of LPS, rather than a mutant CD14, and titrate in S100A9. This would help 
elucidate whether S100A9 and LPS compete for a binding site on CD14. The use of 
antibodies with known binding locations on CD14 could also be used to determine 
whether S100A9 and LPS share a binding site, and in vitro measurements of direct 
binding could be collected with SPR(surface plasmon resonance) or BLI (biolayer 
interferometry). Another important test that could be conducted would be to test for 
CD14 expression levels using a western blot. Should the explanation regarding W45A 
and its effect on protein translation be true, measuring the expression levels of various 
CD14 mutants could answer whether the mutation affects protein expression, rather 
than binding of either ligand.  
Overview  
My work suggests that LPS and S100A9 may use essentially the same binding 
pocket.  This is surprising given their very different structures. However, given these 
differences, and because one mutation to CD14 (F49A) lowered activation of TLR4 via 
S100A9 and had no effect on LPS, I speculate that they may still have slightly different 
binding mechanisms. Since these experiments only demonstrated an effect on activation 
and not on direct binding, it is possible that there may be differences in the binding of 




of CD14, and these mutants only affect activity. Further experimentation could be 
performed to help narrow down these possibilities.  
These findings have implications for future drug development. Without a 
differing binding site, creating a drug that inhibits the binding of one ligand without 
affecting the binding of the other will be difficult. Because of this, drug design may 
need to focus up- or downstream of CD14 to find a suitable target that involves one 
ligand and not the other. In addition to informing drug creation, these findings also have 
implications for our understanding of other TLRs; since other TLRs also recognize 
various MAMPs and DAMPs in an analogous fashion to LPS and S100A9, it is possible 
that they too have their ligands sharing a similar binding site. Experiments like the ones 
performed in this research could be applied to these systems and help inform us of their 
similarities and differences. Additionally, because of these findings, drug designers 
attempting to target these receptors and their ligands may also need to change their 
strategies. However, more research still needs to be conducted to improve our 









Amino acid/residue: Organic compounds that are the base unit of proteins. They 
contain amine and carboxyl functional groups, along with a side chain that is specific to 
each amino acid. There are twenty different naturally occurring amino acids, which 
have the following names, properties, and chemical structures (Sigma). 





Alanine  A Hydrophobic, 
aliphatic 
 
Arginine R Charged, basic 
 
Asparagine N Polar, neutral 
 
Aspartic acid D Charged, acidic 
 
Cysteine C Polar, neutral 
 





Glutamic acid E Charged, acidic 
 
Glycine G Unique, no side 
chain  
Histidine H Charged, basic 
 
Isoleucine I Hydrophobic, 
aliphatic 
 
Leucine L Hydrophobic, 
aliphatic 
 
Lysine K Charged, basic 
 
Methionine M Hydrophobic, 
aliphatic 
 
Phenylalanine F Hydrophobic, 
aromatic 
 





Serine S Polar, neutral 
 
Threonine T Polar, neutral 
 
Tryptophan W Hydrophobic, 
aromatic 
 
Tyrosine Y Hydrophobic, 
aromatic 
 




Assay: A procedure for an experiment. 
BLI: Biolayer interferometry. A way to measure molecular interactions. 
Buffer: An aqueous solution, in this case used as a negative control. 
Canonical receptor: Common receptor used in the biological system.  
CD14: A human protein that is produced by macrophages, and functions as part of the 
innate immune system as a cofactor of TLR4. It can exist in a membrane bound or 
soluble form and is known to bind with LPS and deliver it to TLR4. It is also known to 
be necessary for the activation of TLR4 by S100A9, but the mechanism of this 




Cnidarians: A phylum (evolutionary group) of animals that are mostly marine. 
Includes jellyfish, corals, and sea anemones, among others.  
Co-immunoprecipitation:  A way to identify protein-protein interactions. 
Complex: A group of molecules that work together. For example, the TLR4 complex 
involves TLR4, MD-2, and CD14—all of which work together to recognize danger 
signals.  
Conserved: Maintained across evolutionary time. 
Crystal structure: A representation of the location of atoms. Shows the structure of a 
molecule in 3-dimensional space.  
Cytokines: Small proteins released by the immune system that trigger inflammation.  
Damage-associated molecular pattern (DAMP): Biomolecules of host origin that can 
initiate a noninfectious/sterile inflammatory response. In this case, S100A9 is a DAMP. 
Dimerization: The process in which two molecular subunits join to form one complex. 
ELAM-luciferase: The plasmid that contains the firefly luciferase gene that is 
promoted by NF-KB.  
Endogenous: A substance that originates from within the organism. In this case, 
S100A9 is endogenous.  
Exogenous: A substance that originates from something outside the organism. In this 
case, LPS is exogenous. 
Gram-negative bacteria: A group of bacteria that do not have peptidoglycan (a 




Heterodimer: Two different molecules that come together to form a complex. For 
example, the combination of TLR1 and TLR2 is a heterodimer that recognizes 
triacylated lipopeptides.  
Homodimer: Two of the same molecules that come together. For example, S100A9 
often exists as two of S100A9 molecules bound together, and two TLR4 molecules 
come together to form the TLR4 complex. 
Hydrophobic: The quality of repelling or failing to mix with water. Molecules that are 
hydrophobic are often nonpolar.   
In vitro: Latin for in a test tube. Is used to refer to experiments that do not occur in 
living things. For example, the transfection assay I performed is an in vitro assay.  
In vivo: Latin for in a living organism. Is used to refer to experiments that occur in 
living things. For example, experiments performed on mice are considered to be in vivo.  
kDa: Kilodaltons, a unit of size for molecules.  
Ligand: An endogenous or exogenous molecule that binds with another biomolecule. In 
this case, LPS and S100A9 are ligands for TLR4, MD-2, and CD14.  
Lipid A tails: A chemical component of LPS. Is what binds to the hydrophobic pockets 
of  CD14 and MD-2.  
Lipopolysaccharide (LPS): A major component of the cell wall of Gram-negative 
bacteria. It contains an O antigen, core oligosaccharide, and lipid tails. It is known to 
activate TLR4, and its mechanism of binding with TLR4, MD-2, and CD14 is 
understood.  




MD-2: Also known as lymphocyte antigen 96. It is a cofactor of TLR4, and binds to 
LPS. It is known to be necessary for the activation of TLR4 by S100A9, but the precise 
mechanism is unclear.  
Microbial-associated molecular pattern (MAMP): A biomolecule of microbial origin 
that is recognized by TLRs and can initiate an inflammatory response. In this case, LPS 
is a MAMP. 
Mutagenesis: The process by which genetic information is altered.  
NF-KB: A protein that controls the transcription of specific genes. It becomes activated 
following TLR4 activation. When this protein is activated, it causes the transcription of 
genes that contribute to inflammation.  
O antigen: A chemical portion of some variants of the LPS molecule.  
Oligosaccharides: A large sugar molecule made up of many repeating small sugar 
molecules. Is a chemical portion of LPS.  
Pathogenicity: The state of being pathogenic; having the ability to produce disease.  
Pattern recognition receptor (PRR): Host sensors that recognize molecules from 
specific pathogens. In this case, TLR4 is a PRR.  
pcDNA: A “junk” plasmid used to improve transfection efficiency.  
Plasmid: Small, extrachromosomal DNA that can be replicated independently from 
cellular DNA.  
Progenitors: Early descendants of stem cells that have some classifications of cell type 




P-value: The probability of the observed event occurring, given that the null hypothesis 
is true. P-values < 0.05 indicate that the results are significant, meaning that they likely 
occurred because the mutation had an effect and not because of chance.  
Renilla: The plasmid containing the renilla luciferase gene.  
S100A9: A human protein, elevated in many inflammatory diseases, and known to 
activate TLR4. The precise mechanism of activation is unknown.  
Saturating concentration: The concentration of a ligand when the receptor will always 
be bound to it.  
SPR: Surface plasmon resonance. A way to measure molecular interactions.  
ssRNA: Single stranded RNA; a type of molecule that stores the information to make 
proteins. Is found in many viruses.  
Surface representation: A model of a molecule that represents the space taken up by 
the molecule/its chemical components. For example, while a protein is composed of 
amino acids, and those amino acids are often drawn with a 2-D representation (see 
amino acids table), these structures take up 3-D space, and a surface representation aims 
to show that.  
Titrate: To slowly add more of something while measuring the response due to its 
addition.  
Toll-like Receptor 4 (TLR4): A transmembrane receptor, which when activated 
triggers the intracellular NF-KB pathway, ultimately causing inflammation. It is 
expressed in select immune cells, and functions as a part of the innate immune system. 
Its cofactors are MD-2 and CD14, and it is known to be activated by LPS and S100A9. 




Transcription/Transcribed: The process by which DNA is converted to RNA. 
Transfection: The process of introducing exogenous DNA into cells. The contents of 
this DNA are then read by the cells, and the proteins that it encodes are produced.  
Triacylated lipopetides: A type of molecule found in the cell wall of certain bacteria.   
Truncation: The removal of a string of amino acids. For example, if a protein sequence 
normally has 100 amino acids, and a truncation mutation of the first 50 amino acids is 
created, the resulting mutant only has the first 50 amino acids.  
Western blot: A method used to determine what proteins are present in a sample.  
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